Zhenzhou Yang

10PUBLICATIONS
38CO-AUTHORS
Predictive and prognostic markersMolecular targetsRadiation therapyLiquid biopsiesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 14, 2026
Lung-molGPA may stratify the prognostic impact of TP53 co-mutation in EGFR-mutant lung adenocarcinoma with brain metastases: a multi-center retrospective analysis.

|Jul 10, 2025
NFATc4 Promotes Lung Adenocarcinoma Progression via the CCNB1/CDK1 Pathway and Is a Potential Prognostic Biomarker.

Wendi Yang, Xue Wu, Fanghao Cai

|Dec 18, 2024
Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma.

Guangming Yi, Fanghao Cai, Liangzhong Liu

|Aug 06, 2024
Innate immune dynamics in the context of multisite EGFR mutations in lung adenocarcinoma.

Yuan Peng, Chuan Zeng, Rongxin Liao

|Aug 15, 2023
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.

Xiaojuan Zhou, Laiyan Zhou, Zhuoran Yao

|May 10, 2023
ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma.

Wendi Yang, Kehong Chen, Qian Yu

Pageof 2

Frequent Collaborators

2 joint publications

Yuan Peng

1 joint publications

Fangzhou Song

1 joint publications

Xiaojuan Zhou

1 joint publications

Laiyan Zhou